Currently, patients with bladder cancer are monitored for cancer recurrence or progression by periodic cystoscopy and urine cytology, the frequency of which varies depending on the risk factors ...

While several molecular markers that are used to evaluate the development and prognosis of bladder cancer have been studied, the limited value of these established markers has created the need for ...

Looking ahead, Milowsky said the use of predictive biomarkers is expected to further improve bladder cancer care. These biomarkers can help identify patients at high risk of recurrence ...

The promise of incorporating new treatments and predictive biomarkers to select the right patient for the right treatment every time offers a bright future for bladder cancer patients.

Cell-free DNA (cfDNA) is one of the important biomarkers of liquid biopsy for many malignant cancers like urothelial bladder cancer. However, the use of cfDNA in upper tract urothelial carcinoma ...

Looking ahead, Milowsky said the use of predictive biomarkers is expected to further improve bladder cancer care. These ...

including bladder cancer, prostate cancer and leukemia. Efforts to identify and validate these biomarkers are under way. I also show that a biomarker panel has increased diagnostic sensitivity and ...

Looking ahead, Milowsky said the use of predictive biomarkers is expected to further improve bladder cancer care. These biomarkers can help identify patients at high risk of recurrence ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Urine samples from 20 and 44 patients with bladder cancer undergoing RC were prospectively collected for retrospective ...

Ali Shilatifard, Ph.D., the Robert Francis Furchgott Professor and chair of Biochemistry and Molecular Genetics, was senior author of the study. Mutations in the MLL4 gene, which belongs to a set ...